DBV Technologies Inc. (NASDAQ: DBVT) stock gains by 14.19% in the pre-market trading session. DVB Technologies, based in Bagneux, France, is a publicly-traded French pharmaceutical company. DBV Technologies is notable for developing “Viaskin” technology, which allows allergens or antigens to be administered to intact skin without transferring to the bloodstream.
DBVT stock’ Significant Update
New clinical trial data on the usage of Viaskin Peanut (DBV712) 250 g in children will be discussed at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, Nov. 4-8, 2021, according to DBV Technologies. Two abstracts were accepted, one for an oral presentation and the other for a poster presentation. For those who are not able to attend, these presentations will be posted on DBV’s website, following the meeting’s completion. In addition, DBV will be there in the ACAAI exhibit hall.
New long-term findings from the Phase 3 REALISE (REAL Life Use and Safety of EPIT) research in children 4-11 years of age, demonstrating Viaskin Peanut’s safety over three years and possible impact on health-related quality of life will be discussed (HRQL).
Dr. Pharis Mohideen, Chief Medical Officer of the company commented,
These findings reported at ACAAI add to their knowledge and excitement about Viaskin Peanut’s potential real-world application if it is permitted. As they pursue clinical development, they remain optimistic about Viaskin Peanut’s potential and motivated by the desire to provide patients and their families with much-needed therapeutic choices.
Furthermore,
DBV has also sponsored the 30th Annual FIT Bowl, a game show-style competition that puts teams from fitness programs across the country to the test.
The Company’s flagship product candidate, Viaskin Peanut, is meant to minimize the chances of allergic responses caused by inadvertent exposure to peanuts. Viaskin Peanut is an investigational non-invasive, once-daily epicutaneous patch that aims to re-educate the immune system by delivering microgram levels of peanut antigen. DBV’s proprietary epicutaneous immunotherapy (EPIT) technique, Viaskin Peanut, is a way of administering biologically active chemicals to the immune system through the skin.
